Neuropsychological effects of tiagabine, a potential new antiepileptic drug

Sveinbjörnsdóttir, Sigurlaug; Sander, Josemir W.; Patsalos, PN; Upton, Dominic; Thompson, Pamela J.; Duncan, John S.

doi:10.1016/s1059-1311(05)80160-8

Cited by 71 publications

(39 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 18 studies, over 20% of data were classified as missing. In three studies, the criterion was partially met 39,74,75 and the remaining 11 studies reported insufficient information.…”

Section: Was a Valid Intention-to-treat Analysis Included?mentioning

confidence: 99%

“…49,50,80,[83][84][85][86] Five studies, two of which were abstracts, 40,82 failed to provide the information necessary to judge whether this criterion was met. 39,40,69,82,87 4. Was an appropriate analysis using paired data performed?…”

Section: Did All Participants Have Established Epilepsy With a Constamentioning

confidence: 99%

“…However, details were lacking in 16 studies and four failed to provide details. [38][39][40] Two of these studies were only published in abstract form. 40,41 2.…”

mentioning

confidence: 99%

“…In the remaining studies (63) details were not presented and in two cases it was unclear whether the power calculations were performed before or after the study was completed. 39,42 3. Was the number of participants who were randomised stated?…”

mentioning

confidence: 99%

See 3 more Smart Citations

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Wilby¹,

Kainth²,

Hawkins³

et al. 2005

Health Technol Assess

199

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

show abstract

“…In 18 studies, over 20% of data were classified as missing. In three studies, the criterion was partially met 39,74,75 and the remaining 11 studies reported insufficient information.…”

Section: Was a Valid Intention-to-treat Analysis Included?mentioning

confidence: 99%

Section: Did All Participants Have Established Epilepsy With a Constamentioning

confidence: 99%

“…However, details were lacking in 16 studies and four failed to provide details. [38][39][40] Two of these studies were only published in abstract form. 40,41 2.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Wilby¹,

Kainth²,

Hawkins³

et al. 2005

Health Technol Assess

199

View full text Add to dashboard Cite

show abstract

“…Cognitive functions had not been affected with tiagabine use. 14,30,31 Improvement in motor speed, concentration and verbal fluency has been reported with the use of tiagabine. 32 Usual adult daily dose of tiagabine is 32-56 mg and target range of plasma concentration is 5-70 µg/ml.…”

Section: Tiagabinementioning

confidence: 99%

Impact of anti-epileptic drugs on cognition: a review

Rai

Shah

Yadav

et al. 2016

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Tiagabine add-on for drug-resistant partial epilepsy

Pereira

Marson²,

Hutton

2002

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background-Epilepsy is a common neurological condition, affecting almost 0.5 to 1% of the population. Nearly 30% of people with epilepsy are resistant to currently available drugs. Tiagabine is one of the newer antiepileptic drugs and its effects as an adjunct (add-on) to standard drugs are assessed in this review. Objectives-To evaluate the effects of add-on treatment with tiagabine upon seizures, adverse effects, cognition and quality of life for people with drug-resistant localisation related seizures. Search methods-This is an updated version of the original Cochrane review published in issue 10, 2010. We searched the Cochrane Epilepsy Group's Specialised Register (December 2011), the Cochrane Central Register of Controlled Trials (CENTRAL, issue 4, 2011 of The Cochrane Library), and MEDLINE (1948 to November 2011). No language restrictions were imposed. We also contacted the manufacturers of tiagabine and experts in the field to seek any ongoing or unpublished studies. Selection criteria-Randomised placebo controlled add-on trials of people of any age with localisation related seizures, in which an adequate method of concealment of randomisation was used were included. The studies could be double, single or unblinded and be of parallel or crossover design. They had to have a minimum treatment period of eight weeks. Trials using an active drug control group were also included.

show abstract

Neuropsychological effects of tiagabine, a potential new antiepileptic drug

Cited by 71 publications

References 10 publications

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Impact of anti-epileptic drugs on cognition: a review

Tiagabine add-on for drug-resistant partial epilepsy

Contact Info

Product

Resources

About